SDKX: The first subject has been enrolled in the Phase I clinical trial of GB18 injection

Zhitong
2025.10.29 09:55

Sinovac Biotech announced that its wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd., has successfully completed the first subject enrollment and administration in the Phase I clinical study of "GB18 Injection."

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.